Blood-Based Multi-Cancer Detection Using a Novel Variant Calling Assay (DEEPGEN
DEEPGENTM
cancer detection
cancer screening
cell-free DNA
early detection
liquid biopsy
machine-learning
Journal
Cancers
ISSN: 2072-6694
Titre abrégé: Cancers (Basel)
Pays: Switzerland
ID NLM: 101526829
Informations de publication
Date de publication:
15 Aug 2021
15 Aug 2021
Historique:
received:
26
06
2021
revised:
02
08
2021
accepted:
12
08
2021
entrez:
27
8
2021
pubmed:
28
8
2021
medline:
28
8
2021
Statut:
epublish
Résumé
This is an early clinical analysis of the DEEPGENTM platform for cancer detection. Newly diagnosed cancer patients and individuals with no known malignancy were included in a prospective open-label case-controlled study (NCT03517332). Plasma cfDNA that was extracted from peripheral blood was sequenced and data were processed using machine-learning algorithms to derive cancer prediction scores. A total of 260 cancer patients and 415 controls were included in the study. Overall, sensitivity for all cancers was 57% (95% CI: 52, 64) at 95% specificity, and 43% (95% CI: 37, 49) at 99% specificity. With 51% sensitivity and 95% specificity for all stage 1 cancers, the stage-specific sensitivities trended to improve with higher stages. Early results from this preliminary clinical, prospective evaluation of the DEEPGENTM liquid biopsy platform suggests the platform offers a clinically relevant ability to differentiate individuals with and without known cancer, even at early stages of cancer.
Identifiants
pubmed: 34439258
pii: cancers13164104
doi: 10.3390/cancers13164104
pmc: PMC8392437
pii:
doi:
Types de publication
Journal Article
Langues
eng
Subventions
Organisme : Quantgene Inc.
ID : 001
Références
Blood. 2013 Aug 15;122(7):1214-21
pubmed: 23836561
Mol Diagn Ther. 2015 Dec;19(6):339-50
pubmed: 26400814
Biol Proced Online. 2013 Feb 13;15(1):4
pubmed: 23406336
BMC Health Serv Res. 2014 Sep 12;14:387
pubmed: 25217105
J Clin Oncol. 2014 Feb 20;32(6):579-86
pubmed: 24449238
J Clin Oncol. 2007 Nov 1;25(31):5009-18
pubmed: 17971601
Nat Methods. 2020 Mar;17(3):261-272
pubmed: 32015543
NPJ Precis Oncol. 2019 Jan 28;3:3
pubmed: 30701196
Genome Med. 2016 Mar 02;8(1):24
pubmed: 26932475
BMJ. 2020 Nov 4;371:m4087
pubmed: 33148535
CA Cancer J Clin. 2019 May;69(3):184-210
pubmed: 30875085
Nat Rev Clin Oncol. 2018 Sep;15(9):577-586
pubmed: 29968853
Nat Commun. 2020 Jul 21;11(1):3475
pubmed: 32694610
Nat Med. 2014 Apr;20(4):430-5
pubmed: 24658074
Nat Rev Cancer. 2010 Jan;10(1):2-3
pubmed: 20050335
Science. 2018 Feb 23;359(6378):926-930
pubmed: 29348365
Nat Rev Genet. 2010 Jan;11(1):31-46
pubmed: 19997069
Nat Rev Genet. 2019 Feb;20(2):71-88
pubmed: 30410101
Genes (Basel). 2021 Mar 30;12(4):
pubmed: 33808158
Front Immunol. 2012 Jan 12;2:98
pubmed: 22566887
N Engl J Med. 2017 Mar 30;376(13):1285-1289
pubmed: 28355509
BMC Med Genomics. 2015 Oct 01;8:58
pubmed: 26429708
Lancet Gastroenterol Hepatol. 2019 Dec;4(12):894-895
pubmed: 31648973
Carcinogenesis. 2009 Jul;30(7):1073-81
pubmed: 19468060
CA Cancer J Clin. 2021 Jan;71(1):7-33
pubmed: 33433946
JAMA. 2017 Sep 5;318(9):825-835
pubmed: 28873162
Oncotarget. 2016 Oct 11;7(41):66595-66605
pubmed: 27448974
Semin Oncol. 2009 Feb;36(1):8-37
pubmed: 19179185
JAMA Oncol. 2017 Jul 1;3(7):996-998
pubmed: 27978570
Cancers (Basel). 2019 Jun 19;11(6):
pubmed: 31248203
Sci Transl Med. 2017 Aug 16;9(403):
pubmed: 28814544
Nature. 2009 Nov 5;462(7269):108-12
pubmed: 19847166
Sci Rep. 2018 Apr 16;8(1):6041
pubmed: 29662161
Lab Chip. 2018 Apr 17;18(8):1174-1196
pubmed: 29569666
Int J Mol Sci. 2019 Jun 13;20(12):
pubmed: 31200461
Nat Rev Clin Oncol. 2019 Jul;16(7):409-424
pubmed: 30796368
Nature. 2018 Nov;563(7732):579-583
pubmed: 30429608
Heliyon. 2018 Jul 25;4(7):e00699
pubmed: 30094369